Bolivia vs Egypt, Arab Rep.: Statin use vs. average non-HDL cholesterol levels
Bolivia
3.3
in 2018
Egypt, Arab Rep.
3.3
in 2018
Bolivia rank
95th
Egypt, Arab Rep. rank
95th
Statin use vs. average non-HDL cholesterol levels over time
- Bolivia
- Egypt, Arab Rep.
How they compare
Bolivia currently reports 3.3 against 3.3 in Egypt, Arab Rep., a difference of 0.
Across all 39 years both countries report, Egypt, Arab Rep. has been ahead every year.
Bolivia ranks 95th and Egypt, Arab Rep. ranks 95th of 191 countries.
Egypt, Arab Rep. has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Bolivia | Egypt, Arab Rep. | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.26 | 3.41 | 0.15 | Egypt, Arab Rep. |
| 1990s | 3.35 | 3.56 | 0.21 | Egypt, Arab Rep. |
| 2000s | 3.33 | 3.58 | 0.25 | Egypt, Arab Rep. |
| 2010s | 3.3 | 3.41 | 0.1111 | Egypt, Arab Rep. |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Bolivia or Egypt, Arab Rep.?
- Bolivia, at 3.3 against 3.3 in Egypt, Arab Rep. as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Bolivia and Egypt, Arab Rep.?
- 0, with Bolivia ahead.
- How many years of comparable data are there for Bolivia and Egypt, Arab Rep.?
- 39 years are reported by both, from 1980 to 2018.
- How do Bolivia and Egypt, Arab Rep. rank globally for statin use vs. average non-hdl cholesterol levels?
- Bolivia ranks 95th and Egypt, Arab Rep. ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.